## Clinical Context This patient presents with **enzyme-inducing antiepileptic drug (EIAED)-induced bone disease**: carbamazepine accelerates metabolism of vitamin D, leading to secondary hyperparathyroidism, hypocalcemia, and osteopenia. The elevated alkaline phosphatase reflects increased bone turnover. ## Pathophysiology of EIAED-Induced Bone Disease **Key Point:** Carbamazepine, phenytoin, and phenobarbital induce hepatic CYP3A4 and CYP2C9, which metabolize 25-hydroxyvitamin D to inactive metabolites. This causes: 1. ↓ 25-OH vitamin D levels 2. ↓ Intestinal calcium absorption 3. ↑ Parathyroid hormone (PTH) → secondary hyperparathyroidism 4. ↑ Bone turnover → osteopenia/osteoporosis 5. Hypocalcemia and hyperphosphatasia **High-Yield:** Enzyme-inducing antiepileptics (carbamazepine, phenytoin, phenobarbital) cause bone disease in 20–40% of long-term users. Non-enzyme-inducing alternatives (levetiracetam, valproate, lamotrigine) do NOT cause this complication. ## Management Strategy | Intervention | Rationale | |--------------|----------| | **Calcium + Vitamin D supplementation** | Corrects hypocalcemia and reduces PTH-driven bone loss | | **Monitor bone density (DEXA scan)** | Assess severity; guide escalation | | **Consider EIAED switch** | If bone disease progresses despite supplementation, switch to non-enzyme-inducing agent (LEV, LTG, oxcarbazepine) | | **Avoid immediate discontinuation** | Abrupt carbamazepine withdrawal risks status epilepticus | **Clinical Pearl:** The patient is seizure-free for 2 years — this is a good time to consider gradual tapering and switch to a safer alternative if bone disease is significant. However, the immediate step is supplementation while assessing disease progression. ## Why This Is the Correct Approach Option B addresses both the acute metabolic derangement (hypocalcemia, elevated ALP) AND the underlying cause (EIAED-induced vitamin D metabolism). It avoids the risks of abrupt drug withdrawal while preserving seizure control and allowing time to assess whether bone disease stabilizes or progresses. ## Why Other Options Are Incorrect **Option A (Discontinue carbamazepine immediately):** Abrupt withdrawal of a long-term antiepileptic in a seizure-free patient risks status epilepticus and breakthrough seizures. Carbamazepine must be tapered over weeks to months. Additionally, phenytoin is also an enzyme-inducer and will NOT solve the bone disease problem — it may worsen it. **Option C (Bisphosphonate monotherapy):** While bisphosphonates reduce bone loss, they do NOT address the underlying cause (vitamin D deficiency and secondary hyperparathyroidism). Without correcting vitamin D status, bisphosphonates alone are insufficient and may mask ongoing metabolic derangement. **Option D (Increase carbamazepine dose):** The patient is seizure-free; increasing dose will worsen vitamin D metabolism and accelerate bone loss. This is contraindicated. ## Management Algorithm ```mermaid flowchart TD A["Long-term EIAED use"]:::outcome --> B{"Bone disease screening"}:::decision B -->|Abnormal| C["Confirm: low 25-OH vitamin D, hypocalcemia, elevated ALP"]:::action C --> D["Start calcium 1000–1200 mg/day + vitamin D 800–2000 IU/day"]:::action D --> E["Repeat DEXA in 12 months"]:::action E --> F{"Bone density improved?"}:::decision F -->|Yes| G["Continue supplementation; monitor annually"]:::action F -->|No| H["Taper EIAED; switch to non-enzyme-inducing agent"]:::action H --> I["Seizure control maintained"]:::outcome ``` **Mnemonic:** **EIAED Bone Loss = VIT D Deficiency** - **E**nzyme-**I**nducing **A**ntiepileptic **E**pilepsy **D**rugs - Cause **VIT D** (Vitamin D) deficiency → Hypocalcemia → Hyperparathyroidism → Osteopenia [cite:KD Tripathi 8e Ch 10]
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.